TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26275544

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 81
Study: 25225464

Group type: EXPERIMENTAL
Intervention: Novel traction group (B)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard care group (C)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Ventroflexion traction group (A)
Number of subjects: 216
Study: 23281759

Group type: EXPERIMENTAL
Intervention: 0.03 mg biotin/kg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: 0.06 mg biotin/kg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: 0.09 mg biotin/kg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: 0.12 mg biotin/kg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: 0.15 mg biotin/kg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: 0.18 mg biotin/kg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: 0.21 mg biotin/kg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: 1.5 mg biotin/kg
Number of subjects: 576

Group type: COMPARATOR
Intervention: 0 mg biotin/kg (control)
Number of subjects: 576
Study: 20731476

Group type: COMPARATOR
Intervention: Guanfacine ER (1-4 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guanfacine ER (1-4 mg/day)
Number of subjects: 0
Study: 17035721

Group type: EXPERIMENTAL
Intervention: Dietary supplement (100 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topical cream
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topical lotion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dietary supplement + topical formulations
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no dietary supplement)
Number of subjects: 42
Study: 11203862

Group type: EXPERIMENTAL
Intervention: Etched with H3PO4 for 15 seconds
Number of subjects: 10

Group type: COMPARATOR
Intervention: Etched with H3PO4 for 15 seconds followed by collagen removal with 5% NaOCl for two minutes
Number of subjects: 10
Study: 9127568

Group type: EXPERIMENTAL
Intervention: Patients' views on hospitals making active efforts to improve health care and treatment skills
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Reference to their own clinical data to improve health care and treatment skills
Number of subjects: 293
Study: 1541798

Group type: EXPERIMENTAL
Intervention: Vitamin E (dl‐alpha‐tocopherol), 1200 IU/day, orally for 4 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin E (dl‐alpha‐tocopherol)
Number of subjects: 100
Study: 3031154

Group type: EXPERIMENTAL
Intervention: Oral dextroamphetamine with oral thymoxamine (alpha‐noradrenergic antagonist)
Number of subjects: 0
Study: 30509231

Group type: EXPERIMENTAL
Intervention: Fear avoidance beliefs about work
Number of subjects: 559

Group type: COMPARATOR
Intervention: Fear avoidance beliefs about physical activity
Number of subjects: 559
Study: 26827250

Group type: EXPERIMENTAL
Intervention: SHUTi (online insomnia program based on cognitive behavioural therapy for insomnia)
Number of subjects: 1149

Group type: COMPARATOR
Intervention: HealthWatch (interactive, attention-matched, internet-based placebo control program)
Number of subjects: 1149
Study: 23834300

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 1585

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 1585
Study: 22773036

Group type: EXPERIMENTAL
Intervention: AN69ST membrane (n = 75)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Original AN69 membrane (n = 76)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AN69ST membrane (n = 62)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Original AN69 membrane (n = 56)
Number of subjects: 39
Study: 20163921

Group type: EXPERIMENTAL
Intervention: Gabapentin (GPN) titrated to 2400mg/day
Number of subjects: 45
Study: 18394157

Group type: EXPERIMENTAL
Intervention: 3D echocardiography
Number of subjects: 41
Study: 16238587

Group type: EXPERIMENTAL
Intervention: Salbutamol 30 microl/kg per dose, administered every 15 min
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Salbutamol plus fluticasone 500 microg/dose at 15 and 30 min after first dose of salbutamol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Salbutamol/fluticasone 500 microg/dose, each combined dose administered every 15 min
Number of subjects: 150
Study: 12723744

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg/day
Number of subjects: 8677

Group type: COMPARATOR
Intervention: Aspirin 3 g/day
Number of subjects: 8677

Group type: COMPARATOR
Intervention: Paracetamol 3 g/day
Number of subjects: 8677
Study: 10588560

Group type: EXPERIMENTAL
Intervention: 26-gauge Atraucan (n = 79)
Number of subjects: 158

Group type: COMPARATOR
Intervention: 27-gauge Whitacre (n = 79)
Number of subjects: 158
Study: 8759664

Group type: EXPERIMENTAL
Intervention: SIBDQ (Short Inflammatory Bowel Disease Questionnaire)
Number of subjects: 194
Study: 1920177

Group type: EXPERIMENTAL
Intervention: Behavioural psychotherapy with a nurse therapist
Number of subjects: 42

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Behavioural psychotherapy
Number of subjects: 42
Study: 30909945

Group type: EXPERIMENTAL
Intervention: AA supplement for 15 days prior to the race
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-AA group (no supplement)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: AA group
Number of subjects: 41
Study: 27677411

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1723

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1723

Group type: COMPARATOR
Intervention: Heparin plus tirofiban
Number of subjects: 1723
Study: 25776953

Group type: EXPERIMENTAL
Intervention: Prednisone increase
Number of subjects: 44
Study: 23561287

Group type: EXPERIMENTAL
Intervention: Intranasal diazepam solution (10mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal diazepam suspension (10mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous diazepam (5mg)
Number of subjects: 24
Study: 22129158

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rtPA)
Number of subjects: 3035
Study: 19879462

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter guidance
Number of subjects: 425

Group type: COMPARATOR
Intervention: Clinical assessment to guide therapy
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Improvement in HRQOL by 1 month
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: No improvement in HRQOL by 1 month
Number of subjects: 425
Study: 17664404

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788
Study: 16274603

Group type: EXPERIMENTAL
Intervention: 5% O2 concentration during embryo culture
Number of subjects: 712

Group type: COMPARATOR
Intervention: 20% O2 concentration during embryo culture
Number of subjects: 712
Study: 12140498

Group type: EXPERIMENTAL
Intervention: Accelerated emergency department-based strategy with low-molecular-weight heparin and early cardioversion to sinus rhythm
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional approach of hospital admission
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 10194770

Group type: EXPERIMENTAL
Intervention: HIV myelitis in drug users (17%)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Opportunistic infections
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lymphomas
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Moderate or severe vacuolar myelopathy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HIV proviral load
Number of subjects: 90
Study: 7483087

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride (100 mg IV twice daily for four days, followed by 150 mg orally twice daily for five days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 24
Study: 2106334

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) infusion before and during CPB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study: 6117681

Group type: COMPARATOR
Intervention: Neither antibiotics nor myringotomy
Number of subjects: 171

Group type: COMPARATOR
Intervention: Myringotomy only
Number of subjects: 171

Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 171

Group type: COMPARATOR
Intervention: Both antibiotics and myringotomy
Number of subjects: 171
Study: 31808012

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31989162

Group type: COMPARATOR
Intervention: Placebo beverage condition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Acute alcohol intoxication
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Emotion-regulation task
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Self-reported anger experiences
Number of subjects: 38
Study: 27773351

Group type: EXPERIMENTAL
Intervention: Pan-scan protocol
Number of subjects: 426
Study: 25862215

Group type: EXPERIMENTAL
Intervention: Cooperstown cocktail + oral LDX 70 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cooperstown cocktail
Number of subjects: 30
Study: 23541571

Group type: EXPERIMENTAL
Intervention: Normal pretreatment serum LDH level (109.0-245.0 U/L)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Elevated pretreatment serum LDH level (≥245.0 U/L)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Normal LDH (median point of 177.0 U/L)
Number of subjects: 400

Group type: COMPARATOR
Intervention: LDH level 178.0-245.0 U/L
Number of subjects: 400
Study: 21408060

Group type: EXPERIMENTAL
Intervention: Psychologically enhanced website intervention
Number of subjects: 7935

Group type: COMPARATOR
Intervention: Typical alcohol website providing information on potential harms of alcohol (Control)
Number of subjects: 7935
Study: 19733606

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17109335

Group type: EXPERIMENTAL
Intervention: Vaccine (rAd5 vector HIV-1 candidate vaccine) at dose levels of 10^9 (n=10), 10^10 (n=10), or 10^11 (n=10) particle units
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vaccine (rAd5 vector HIV-1 candidate vaccine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14718327

Group type: EXPERIMENTAL
Intervention: Palliative care team consultations, advance care planning, psychosocial support, and family caregiver training.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Palliative care team consultations.
Number of subjects: 90
Study: 11758237

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg every 12 hours (or 1g every 12 hours if necessary)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1g/1g every 12 hours if necessary)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 112

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 112
Study: 9398796

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (blood glucose 14.8 +/- 0.86 mmol/liter)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Euglycemia (blood glucose 3.8 +/- 0.6 mmol/liter)
Number of subjects: 11
Study: 10151019

Group type: EXPERIMENTAL
Intervention: 6Fr Novoste RCA catheters
Number of subjects: 100

Group type: COMPARATOR
Intervention: 6Fr Judkins RCA catheters
Number of subjects: 100
Study: 2959448

Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate 150mg
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Depot-medroxyprogesterone acetate 100mg
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Both dosages of DMPA
Number of subjects: 1216
Study: 29406180

Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 4 mg
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 8 mg
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (i.v. normal saline)
Number of subjects: 115
Study: 27397662

Group type: EXPERIMENTAL
Intervention: Fluid accumulation in the neck (ΔNC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluid accumulation in the neck (ΔNFV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pre-sleep neck circumference (NC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neck circumference (NC) and neck fluid volume (NFV)
Number of subjects: 20
Study: 24067888

Group type: EXPERIMENTAL
Intervention: Neridronate (100 mg, monthly i.v.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Infliximab (5 mg/kg, standard therapy)
Number of subjects: 60
Study: 22486380

Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement (ERL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mechanical scaling and root planing (SRP)
Number of subjects: 28
Study: 20831543

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 or 30 mg daily) for 3 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Withdrawal of pioglitazone after 3 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment in post-menopausal women
Number of subjects: 49
Study: 18584464

Group type: EXPERIMENTAL
Intervention: Nicotine Dependence Syndrome Scale (NDSS) Priority subscale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wisconsin Inventory of Smoking Dependence Motives (WISDM) Tolerance subscale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fagerstrom Test of Nicotine Dependence (FTND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WISDM subscales
Number of subjects: 0
Study: 15671089

Group type: EXPERIMENTAL
Intervention: GH treatment for 6 months (group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GH deprivation for 6 months (group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GH addition for 6 months (group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no GH for 6 months, group B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mean IMT after 6 months (group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mean IMT after 6 months (group B)
Number of subjects: 34
Study: 12135281

Group type: EXPERIMENTAL
Intervention: Oral ARTS (135 mg; 352 micromol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral DHA (120 mg; 422 micromol)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined bioavailability of ARTS and DHA in ARTS perfusions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hepatic bioavailability of ARTS (39 microM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hepatic bioavailability of DHA in ARTS perfusions (35 microM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hepatic bioavailability of DHA in DHA perfusions (35 microM)
Number of subjects: 8
Study: 10463312

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prepulse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7593499

Group type: EXPERIMENTAL
Intervention: Intravenous albumin (20 g) administered immediately after oocyte retrieval
Number of subjects: 40
Study: 2299810

Group type: EXPERIMENTAL
Intervention: Cuprammonium (Cup) dialyzer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polysulfone (PS) dialyzer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant C5a
Number of subjects: 0
Study: 6990675

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg the night before and 400 mg on the morning of surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31614277

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: BAS reward sensitivity
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Diagnosis of BD II
Number of subjects: 76
Study: 31393651

Group type: EXPERIMENTAL
Intervention: Nano-ceramic onlays (Lava Ultimate/3M)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Leucite‐reinforced ceramic onlays (IPS EmpressCAD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both nano-ceramic and leucite-reinforced onlays
Number of subjects: 120
Study: 30115552

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 77
Study: 27699743

Group type: EXPERIMENTAL
Intervention: Foam dressing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 60
Study: 25047038

Group type: EXPERIMENTAL
Intervention: 3% SB705498 cream
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22232454

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 265

Group type: COMPARATOR
Intervention: atovaquone-proguanil
Number of subjects: 265

Group type: COMPARATOR
Intervention: artesunate-mefloquine
Number of subjects: 265
Study: 21284248

Group type: EXPERIMENTAL
Intervention: New Pro‐Argin formula dentifrice containing 8.0% arginine, a high cleaning calcium carbonate system and 1450 ppm fluoride
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Previously validated Pro‐Argin formula dentifrice containing 8.0% arginine, calcium carbonate and 1450 ppm fluoride
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control toothpaste containing calcium carbonate and 1450 ppm fluoride
Number of subjects: 122
Study: 18691193

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment (no Rx)
Number of subjects: 25
Study: 16409095

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) used to evaluate AACD
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control sites (not specified)
Number of subjects: 20
Study: 12576261

Group type: EXPERIMENTAL
Intervention: Raloxifene (combined doses of 60 mg/day and 120 mg/day)
Number of subjects: 943

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 943
Study: 10999870

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 microg daily
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Evening medication (all groups)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Morning medication (all groups)
Number of subjects: 122
Study: 8997917

Group type: EXPERIMENTAL
Intervention: spouse‐assisted pain‐coping skills training
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: CST (conventional CST intervention with no spouse involvement)
Number of subjects: 88

Group type: COMPARATOR
Intervention: AE‐SS (arthritis education‐spousal support control condition)
Number of subjects: 88
Study: 1467077

Group type: COMPARATOR
Intervention: Cricoid pressure
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: No cricoid pressure
Number of subjects: 42
Study: 6084452

Group type: EXPERIMENTAL
Intervention: Procyanidolic oligomers (PCO) 300 mg/day for 5 days before and 5 days after surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Procyanidolic oligomers (PCO)
Number of subjects: 32
Study: 31828172

Group type: EXPERIMENTAL
Intervention: Shenqi pollen capsules (SPCs) for 7 weeks
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Shenqi pollen capsules (SPCs)
Number of subjects: 288
Study: 28941598

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) - 4 minutes at 80% VO2peak followed by 3 minutes at 50% VO2peak, 4 weeks, 400 kcal/session
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise Training (MICT) - 55% VO2peak, 60 minutes, 4 weeks, 400 kcal/session
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 18
Study: 27219884

Group type: EXPERIMENTAL
Intervention: HUCMSC transplantation after angioplasty
Number of subjects: 53

Group type: COMPARATOR
Intervention: Angioplasty (Control)
Number of subjects: 53
Study: 24844538

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with Amniotic Membrane Transplant (AMT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin-C (MMC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Transplant (AMT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mitomycin-C (MMC)
Number of subjects: 52
Study: 22335885

Group type: EXPERIMENTAL
Intervention: Splinting
Number of subjects: 52
Study: 19062223

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (US) technique
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard landmark (LM) technique
Number of subjects: 66
Study: 18332764

Group type: EXPERIMENTAL
Intervention: Immediate placement condition (46 implants)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Delayed placement condition (36 implants)
Number of subjects: 64
Study: 15726322

Group type: EXPERIMENTAL
Intervention: Intraoperative tissue samples
Number of subjects: 63

Group type: COMPARATOR
Intervention: Swab samples
Number of subjects: 63

Group type: COMPARATOR
Intervention: Patients receiving systemic antimicrobial treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients without prior antibiotic treatment
Number of subjects: 63
Study: 12904977

Group type: EXPERIMENTAL
Intervention: Lithium augmentation therapy
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study: 10499943

Group type: EXPERIMENTAL
Intervention: Practice based on the Ottawa Knee Rule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice based on physician judgment
Number of subjects: 0
Study: 8932071

Group type: EXPERIMENTAL
Intervention: 10 units heparin/ml saline (HS)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 118
Study: 1859059

Group type: EXPERIMENTAL
Intervention: Albuterol (100 micrograms/puff, three times two puffs)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (three times two puffs)
Number of subjects: 36
Study: 6378117

Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 185